Abstract
Treatments for chronic refractory cough that act centrally are not particularly effective and are often accompanied by adverse effects. A number of medications targeting purinergic receptors in vagal afferent nerves have recently been under investigation. One of them, gefapixant, has been approved for use in Japan and Switzerland. However, it has not been approved by the US Food and Drug Administration or the European Medicines Agency yet. Camlipixant, another drug in this class, is currently being studied in a phase III trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have